IMPORTANT INVESTOR ALERT: Lundin Law PC Announces Securities Class Action Lawsuit against Seres Therapeutics, Inc. and Reminds Investors with Losses In Excess of $100,000 to Contact the Firm

LOS ANGELES, CA / ACCESSWIRE / October 27, 2016 / Lundin Law PC, a shareholder rights firm, announces a class action lawsuit against Seres Therapeutics, Inc. (“Seres Therapeutics” or the “Company”) (Nasdaq: MCRB) concerning possible violations of federal securities laws between June 25, 2015 and July 29, 2016 inclusive (the “Class Period”). Investors who purchased or otherwise acquired shares during the Class Period should contact the firm in advance of the November 28, 2016 lead plaintiff motion deadline.

To participate in this class action lawsuit, click here. You can also call Brian Lundin, Esquire, of Lundin Law PC, at 888-713-1033, or e-mail him at brian@lundinlawpc.com.

No class has been certified in the above action yet. Until a class is certified, you are not considered represented by an attorney. You may also choose to do nothing and be an absent class member.

The complaint alleges that during the Class Period, Seres Therapeutics made materially false and misleading statements and/or failed to disclose material facts about its lead drug product candidate SER-109, touting its potential and efficacy. On July 29, 2016, the Company announced that the Phase 2 clinical trial of SER-109 did not meet its primary endpoint. When this information was disclosed to the public, the stock price of Seres Therapeutics declined, which caused investors harm.

Lundin Law PC was established by Brian Lundin, a securities litigator based in Los Angeles dedicated to upholding shareholders’ rights.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Contact:

Lundin Law PC
Brian Lundin, Esq.
Telephone: 888-713-1033
Facsimile: 888-713-1125
brian@lundinlawpc.com
http://lundinlawpc.com/

SOURCE: Lundin Law PC

ReleaseID: 447838